(VCBeat) Feb. 9, 2021 -- Beijing Changmugu Medical Technology Co., Ltd. ("Changmugu"), a high-tech company of orthopedic AI and surgical robots, recently announced the closing of a Series Pre-B round of 120 million yuan. This round was led by Oriza Seed Capital, with participation from YuanBio Venture Capital, Legend Star and Shenzhen Xinchuang. WinX Capital acted as the financial adviser. 

The funds raised are earmarked for the development and clinical trials of orthopedic surgical robots, the marketing of orthopedic AI-powered products, and preparation for global registration and marketing.

Previously, Changmugu has completed four rounds of financing, including the seed round led by FreesFund, the Series Pre-A round led by Legend Star, the Series A round led by Qihai Fund of Zhongguancun Development Group, and the Series A+ round led by Lenovo Capital.

Founded in 2017, Changmugu focuses on orthopedic artificial intelligence, providing a series of artificial intelligence solutions for the whole process of orthopedic surgery, including preoperative evaluation, surgical planning, 3D printing, and customized surgical navigation guiding. 

In order to solve the pain points of traditional orthopedic surgeries, Changmugu has cooperated with orthopedic experts from more than 50 first-class hospitals at grade 3, leading their rich operation experience into an algorithm for the deep learning of AI, and developed AIJOINT, the AI-assisted 3D surgical Solution for Joint replacement, for doctors to provide the overall solution of the whole surgical process, covering preoperative planning, intraoperative navigation, and postoperative evaluation. The whole series includes AIUNI, AIKNEE, AIHIP, and AIREVISION. 

AIJOINT has been highly praised by many top surgical experts for its ability to meet the actual clinical needs of doctors.

In addition, based on the advanced orthopedic AI-based system, Changmugu has equipped the AI brain with a surgical robot that can accurately execute the planning operations and launched the surgical robot for joint replacement.

Oriza Seed Capital is the early-stage investment management platform of Oriza Holdings, focusing on seed funds and growth funds. Oriza Seed Capital mainly invests in early and growth-stage start-ups in TMT and Healthcare. At present, the company has set up subsidiaries or offices in Suzhou, Shanghai, Hangzhou, Guangzhou, Nanjing and Beijing.

Founded at BioBay of Suzhou Industrial Park and portfolio spreading China and globally, YuanBio Venture Capital focuses on early and growth-stage life science and healthcare investment. Its total AUM is close to 5 billion RMB. Portfolio includes over 70 companies across BioPharma, MedTech, IVD and Health Services sectors. YuanBio Venture Capital aims to be one of the most successful healthcare venture capital firms in China.